Long term effects of a single dose of intravenous Ibandronate

Journal of Musculoskeletal Neuronal Interactions

Volumn 3, Issue 1, 2003, Pages 77-82

  Burckhardt, Peter ^a   Husi B ^a   Thiebaud D ^a   Jacquet, A F ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Bone metabolism; Ibandronate; Intravenous biphosphonate; Normal volunteers

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; OSTEOCALCIN; PAMIDRONIC ACID; PEPTIDE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HYPERCALCEMIA; LONG TERM CARE; MALE; OPTIMAL DRUG DOSE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SINGLE DRUG DOSE;

EID: 0037360440     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Garnero P, Chapuy M-C, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996; 11:1531-1538.
2. Rosen CJ, Chesnut CH, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997; 82:1904-1910.
3. Thiébaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, Gobelet C. Two year's effectiveness of intravenous Pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 1994; 4:76-83.
4. Thiébaud D, Jaeger PH, Jacquet AF, Burckhardt P. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AhPrBP. J Clin Oncol 1988; 6:762-768.
5. Adami S, Zamberlan N, Mian M, Dorizzi R, Rossini M, Braga B, Gatti D, Bertoldo F, Locascio V. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. Bone Miner 1994; 25:75-82.
6. Netelenbos JC, van Ginkel FC, Lips P, Leeuwenkamp OR, Barto R, van der Vijgh WJF, van der Wiel H, Hackeng WHL. Effect of a single infusion of aminohydroxypropylidene on calcium and bone metabolism in healthy volunteers monitored during 2 months. J Clin Endocrinol Metab 1991; 72:223-228.
7. Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder F, Juttmann JR, Schöter KH. Three monthly intravenous injections of Ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103:298-307.
8. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MN, Gertz BJ, Sciberras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG. Elimination and biochemical responses to intravenous Alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997; 12:1700-1707.
9. Passeri M, Baroni MC, Pedrazzoni M, Pioli G, Barbagallo M, Costi D, Biondi M, Girasole G, Arlunno B, Palummeri E. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1, 1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 1991; 15:237-247.
10. Vasikaran SD, Khan S, McCloskey EV, Kanis JA. Sustained response to intravenous Alendronate in postmenopausal osteoporosis. Bone 1995; 17:517-520.
11. Heikkenen JE, Selander KS, Laitinen K, Arnala I, Väänänen HK. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss. J Bone Miner Res 1997; 12:103-110.
12. Stepan J, Burckhardt P, Hana V. Increase by 10% of spine bone mineral density and effect on bone markers of three-monthly intravenous injections of Ibandronate in osteoporosis in men with Klinefelter's syndrome. J Bone Miner Res 2000; 15(Suppl.1):F382-S-226.